Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
XOPENEX |
| Manufacturer |
|
Sepracor, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
β2-agonist. |
| Generic Name |
|
Levalbuterol (as HCl) (single-isomer albuterol) 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL; per vial; inhalation soln; preservative-free. |
| Also |
• XOPENEX CONCENTRATE
• XOPENEX HFA
|
| Indications |
|
Bronchospasm. |
| Children |
|
<6 years: not recommended. 6–11 years: 0.31mg by nebulization 3 times daily; max 0.63mg 3 times daily. |
| Adults |
|
Initially 0.63mg by nebulization 3 times daily at 6–8 hr intervals; may increase to 1.25mg 3 times daily. |
| Precautions |
|
Do not exceed recommended dose; monitor for increased need. Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Seizure disorders. Diabetes. Hyperthyroidism. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Monitor digoxin. Caution with other drugs that may lower serum potassium. |
| Adverse Reactions |
|
Nervousness, tremor, cough, tachycardia, headache, GI upset, leg cramps, dizziness, turbinate edema, hypokalemia, paradoxical bronchospasm; children: also asthenia, diarrhea. |
| How Supplied |
Inhaler w. actuator (200 inh)—15g
Soln 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL—24 vials
Concentrate 1.25mg/0.5mL—30 vials |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
